Étiquette : efficacité

Whole-plant Cannabis Linked to Large Reduction in Seizures Kelli Whitlock Burton, Medscape, 2021.

Whole-plant Cannabis Linked to Large Reduction in Seizures Kelli Whitlock Burton Medscape - Dec 29, 2021. https://www.medscape.com/viewarticle/965756   Whole-plant cannabis is linked to a significant reduction in seizures in children with severe treatment-resistant epilepsy, early research suggests. In a small case series, children with severe treatment-resistant epilepsy treated with a range of whole-plant extract cannabis-based medical products (CBMPs) reported an 86% reduction in monthly seizures. All participants had no improvement with traditional antiepileptic drugs (AEDs). The study adds to a small but growing body of research investigating whole-plant cannabis medicines containing tetrahydrocannabinol (THC) in pediatric epilepsies. Rayyan Raja Zafar "Although we have previously noted the superior efficacy of whole-plant medical cannabis is a previous [...]

Lire la suite

Long-Term Efficacy for Epidiolex in Resistant Epilepsy, Pauline Anderson, Medscape.com, 2018.

Long-Term Efficacy for Epidiolex in Resistant Epilepsy Pauline Anderson  Medscape - Dec 17, 2018. https://www.medscape.com/viewarticle/906653   NEW ORLEANS — Results of open-label extension trials show the recently approved drug Epidiolex (GW Pharmaceuticals), a purified formulation of cannabidiol (CBD), is safe and effective beyond a year in patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome, two rare and resistant epilepsy types. "We now have long-term data to say that it still works; the efficacy is not going to drop off, and more importantly, it's still going to be safe and you're not going to learn anything new down the road," study author Anup D. Patel, MD, Section Chief of Pediatric Neurology, [...]

Lire la suite

L’évaluation et l’efficacité des psychothérapies psychanalytiques et de la psychanalyse, Thomas Rabeyron, 2021

L’évaluation et l’efficacité des psychothérapies psychanalytiques et de la psychanalyse The evaluation and the efficacy of psychoanalytical therapies and psychoanalysis Thomas Rabeyron L’Évolution Psychiatrique, 2021, 86, 3, 455-488 Doi : 10.1016/j.evopsy.2020.07.003   Résumé Objectif. – Cet article propose une revue de littérature concernant l’évaluation et l’efficacité des psychothérapies psychanalytiques et de la psychanalyse (PPP). Méthode. – Après avoir proposé une vue d’ensemble de l’évaluation des psychothérapies, nous reprenons les travaux portant sur l’évaluation empirique et quantitative des PPP avant de nous centrer sur leur évaluation qualitative et processuelle.Résultats. – Les résultats des études menées en ce domaine démontrent que les psychothérapies sont efficaces aussi bien sur le court [...]

Lire la suite

Real life Experience of Medical Cannabis Treatment in Autism : Analysis of Safety and Efficacy, Lihi Bar-Lev Schleider et al., 2019

Real life Experience of Medical Cannabis Treatment in Autism : Analysis of Safety and Efficacy Lihi Bar-Lev Schleider, Raphael Mechoulam, Naama Saban, Gal Meiri & Victor Novack Scientific Reports, Nature.com, 2019, 9, 200, 1-7 Doi : 10.1038/s41598-018-37570-y   There has been a dramatic increase in the number of children diagnosed with autism spectrum disorders (ASD) worldwide. Recently anecdotal evidence of possible therapeutic effects of cannabis products has emerged. The aim of this study is to characterize the epidemiology of ASD patients receiving medical cannabis treatment and to describe its safety and efficacy. We analysed the data prospectively collected as part of the treatment program of [...]

Lire la suite

Medical Cannabis Use Rising Among Older Adults, Pauline Anderson, Medscape Medical News, 2021

Medical Cannabis Use Rising Among Older Adults Pauline Anderson Medscape Medical News ©March 22, 2021   More individuals are using medical cannabis, but the increase appears to be more pronounced among seniors, new research suggests. Results of a large Canadian survey study show that the proportion of older users among total users increased from 17.6% before 2017 to 26.7% in 2018 and 31.2% in 2019. The proportion of older users was 22.7% in 2020, but there were fewer participants in this latest sample (8869 in 2019 and 5644 in 2020). The majority of older respondents reported that they use cannabis to relieve pain and prefer cannabidiol [...]

Lire la suite

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD, Deborah Brauser, Medscape.com, 2021

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD Deborah Brauser Medscape. com, January 18, 2021 Medscape Medical News © 2021 www.medscape.com/viewarticle/944282_print   Repeated intravenous infusions of ketamine provide rapid relief for patients with posttraumatic stress disorder (PTSD), new research suggests. In what investigators are calling the first randomized controlled trial of repeated ketamine administration for chronic PTSD, 30 patients received six infusions of ketamine or midazolam (used as a psychoactive placebo) over 2 consecutive weeks. Between baseline and week 2, those receiving ketamine showed significantly greater improvement than those receiving midazolam. Total scores on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) for the first group were almost 12 points [...]

Lire la suite

Development of Ketamine Administration as a Treatment for Chronic PTSD, Abigail B. Collins et al., 2020

Development of Ketamine Administration as a Treatment for Chronic PTSD Abigail B. Collins, BS; Sarah B. Rutter, MA; and Adriana Feder, MD Psychiatric Annals, 2020, 50, (2), 68-76. doi : 10.3928/00485713-20200109-01   ABSTRACT Posttraumatic stress disorder (PTSD) is a highly prevalent, chronic, and dis-abling condition for which currently available pharmacotherapies are insuf-ficiently effective. Ketamine, which is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a promising and rapid-act-ing novel treatment intervention for this disorder. Findings from a proof-of-concept, randomized, controlled cross-over study of single-dose intravenous ketamine administration (compared to single-dose midazolam) in patients with chronic PTSD suggest that ketamine is associated with rapid improvement in [...]

Lire la suite

Short-term effects of cannabis consumption on cognitive performance in medical cannabis patients, Phillip Olla et al., 2019

Short-term effects of cannabis consumption on cognitive performance in medical cannabis patients Phillip Olla, Nicholas Rykulski, Jessica L. Hurtubise, Stephen Bartol, Rachel Foote, Laura Cutler, Kaitlyn Abeare, Nora McVinnie, Alana G. Sabelli, Maurissa Hastings, and Laszlo A. Erdodi Applied Neuropsychology : Adult, 2019, 1-11. Doi : 10.1080/23279095.2019.1681424   ABSTRACT This observational study examined the acute cognitive effects of cannabis. We hypothesized that cognitive performance would be negatively affected by acute cannabis intoxication. Twenty-two medical cannabis patients from Southwestern Ontario completed the study. The majority (n¼13) were male. Mean age was 36.0 years, and mean level of education was 13.7 years. Participants were administered the same brief neurocognitive battery three times during [...]

Lire la suite

Quality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases : A 12-Month Longitudinal Study, BOUSO J.C. et al., 2020

Quality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases : A 12-Month Longitudinal Study. BOUSO J.C., JIMENEZ-GARRIDO D., ONA G., WOZNICA D., dos SANTOS R.G., HALLAK J.E.C., PARANHOS B. A., de ALMEIDA MENDES F., YONAMINE M. et al. : Phytotherapy Research, 2020. Doi : 10.1002/ptr.6639 © 2020 John Wiley & Sons, Ltd. Abstract The number of patients using cannabis for therapeutic purposes is growing worldwide. While research regarding the treatment of certain diseases/disorders with cannabis and cannabinoids is also expanding, only a few longitudinal studies have assessed the mid-term impacts of medical cannabis use on psychological variables and quality [...]

Lire la suite

Cannabis Use Moderates the Relationship between Pain and Negative Affect in Adults with Opioid Use Disorder, Marian Wilson et al.,

Cannabis Use Moderates the Relationship between Pain and Negative Affect in Adults with Opioid Use Disorder Marian Wilson, Hannah Y. Gogulski, Carrie Cuttler,  Teresa L. Bigand, Oladunni Oluwoye,Celestina Barbosa-Leiker, MaryLee A. Roberts Addictive Behaviors, 2017, 30 p. doi : 10.1016/j.addbeh.2017.10.012   Abstract Introduction : Adults in Medication-Assisted Treatment (MAT) for opioid addiction are at risk for substance use relapse and opioid overdose. They often have high rates of cannabis use and comorbid symptoms of pain, depression, and anxiety. Low levels of self-efficacy (confidence that one can self-manage symptoms) are linked to higher symptom burdens and increased substance use. The effects of cannabis use on symptom management [...]

Lire la suite